A Dioscorea septemloba Thunb extract, coded LB809, ameliorates psoriasis-like cutaneous inflammation by suppressing LYN-mediated STAT3 phosphorylation and disrupting exosomal LRG1 communication between keratinocytes and macrophages. That is the finding presented in the Journal of Investigative Dermatology, Volume 146, Issue 10, Supplement, published October 2026, with Xiaodong Sun as author.

The study sits at the intersection of two active threads in psoriasis research: botanical-derived compounds and intercellular signaling. LB809 is an extract of Dioscorea septemloba Thunb, a plant species used in traditional East Asian medicine. The work gives it a defined molecular target.

What pathway does LB809 hit?

The reported mechanism runs through the LYN–STAT3 axis. LYN is a Src-family kinase; STAT3 is a transcription factor central to psoriatic inflammation, driving keratinocyte proliferation and inflammatory gene expression. According to the publication, LB809 suppresses LYN-mediated phosphorylation of STAT3. That phosphorylation event is the switch that turns STAT3 on. Blocking it dials down the downstream inflammatory program.

In plain words: the extract appears to cut the signal before it amplifies.

Where do exosomes come in?

The second half of the finding concerns how skin cells talk to immune cells. The study reports that LB809 affects exosomal LRG1 — intercellular communication carried in exosomes, the small vesicles cells release to deliver proteins and RNA to neighbors. Here the conversation is between keratinocytes, the predominant epidermal cell type, and macrophages, the innate immune cells that sustain psoriatic plaques. LRG1 (leucine-rich alpha-2-glycoprotein 1) is the cargo implicated in that exchange.

The framing matters for dermatology. Psoriasis is increasingly understood as a disease of dysregulated crosstalk, not just aberrant signaling within one cell type. A compound that modulates both the STAT3 pathway and the vesicle traffic between keratinocytes and macrophages would, if confirmed, act at two levels of the inflammatory loop.

How solid is the evidence?

Readers should weigh the publication format. The data appear in a JID supplement issue — supplement issues typically carry meeting abstracts and short reports rather than full-length articles. The inflammation model is described as psoriasis-like, meaning an experimental model of cutaneous inflammation rather than a human clinical trial. No PASI scores, cohort sizes, or dosing details appear in the available publication record for this item, so effect sizes cannot be stated here.

What the record does establish:

• Compound: LB809, an extract of Dioscorea septemloba Thunb
• Model: psoriasis-like cutaneous inflammation
• Mechanism: suppression of LYN-mediated STAT3 phosphorylation
• Second mechanism: disruption of exosomal LRG1 transfer between keratinocytes and macrophages
• Publication: Journal of Investigative Dermatology, Vol. 146, Issue 10, Supplement, October 2026, author Xiaodong Sun

The bottom line is mechanistic, not clinical: a plant-derived compound with a named molecular target in a preclinical psoriasis model.

Why STAT3 and LRG1 matter

STAT3 activation in keratinocytes is a well-established feature of psoriatic skin, linked to the IL-23/IL-17 axis that biologics such as IL-17 and IL-23 inhibitors already target upstream. A small-molecule or botanical suppressor of STAT3 phosphorylation, acting intracellularly rather than on cytokines in circulation, would represent a different therapeutic geometry. LRG1, meanwhile, has drawn attention in dermatology research for roles in angiogenesis and fibrosis, and its delivery via keratinocyte-derived exosomes to macrophages adds a cell-to-cell route that circulating drugs may not reach easily.

Whether LB809 can translate from a psoriasis-like model to human trial endpoints — PASI 75 or PASI 90 responses, safety in chronic use, standardized extract composition — remains the open question, and one this supplement publication does not answer. Derm Field will track whether the Sun group follows with full-length mechanistic data or a first-in-human protocol.